FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer
VANCOUVER, BC, May 11, 2021 -- (Healthcare Sales & Marketing Network) -- Bold Therapeutics, a clinical-stage biopharmaceutical company, is announcing that the U.S. Food & Drug Administration (FDA) has granted BOLD-100 an Orphan Drug Designation (ODD) in t... Biopharmaceuticals, Oncology, FDA Bold Therapeutics, BOLD-100, ruthenium, Gastric Cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | Grants | Marketing | Pharmaceuticals